TSM, JNJ, and Abbott Post Record Q2 Results and Raise Full-Year Guidance

Key Facts

In a move reflecting the resilience of the healthcare and semiconductor sectors, major global players have signaled strong growth momentum during the current earnings season. According to reports, Abbott Laboratories, Taiwan Semiconductor (TSM), and Johnson & Johnson (JNJ) delivered record-breaking financial results for the second quarter of 2026. This performance was underpinned by robust operational execution, which has bolstered management confidence for the remainder of the year.

Following these positive outcomes, all three companies raised their full-year financial guidance, providing a bullish signal for investors across these critical industries. Per market data, the recent price action reflects investor response to these upgraded outlooks and the potential for continued profitability growth among these large-cap leaders.

At the close of July 28, 2026, TSM stood at $391.58 and JNJ at $267.89, while ABT was positioned at $104.49 (as of July 27, 2026). With no major upcoming catalysts listed in the immediate economic calendar, traders will focus on whether these instruments can maintain their current levels and meet the newly raised annual targets in the coming months.